^
Association details:
| Biomarker: | BRCA1 mutation + HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Published date:
06/03/2021
Excerpt:
...patients with human epidermal growth factor receptor 2 (HER2)-negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants....At a prespecified event-driven interim analysis with a median follow-up of 2.5 years, the 3-year invasive disease-free survival was 85.9% in the olaparib group...
DOI:
10.1056/NEJMoa2105215
Trial ID:
